Catalyst Event
Merck and Co Inc (MRK) · Other
From Akros SCHK HK-US Biotech Index (ASHUBIO)
3/29/2026, 12:00:00 AM
Announced positive detailed results from the Phase 2 CADENCE trial for WINREVAIR™ (sotatercept-csrk) on 2026-03-29, meeting the primary endpoint; estimated to have a medium impact of ~5% due to positive clinical data.
Korean Translation
2026-03-29에 WINREVAIR™(소타터셉트-csrk)의 2상 CADENCE 임상시험에서 1차 평가변수를 충족하는 긍정적인 결과를 발표함; 긍정적인 임상 데이터로 인해 약 5%의 중간 정도 영향이 예상됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
High importance is estimated due to the potential for significant price volatility for Pfizer's Q1 2026 earnings release and conference call, scheduled.
5/5/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release and conference call scheduled; typically results in moderate price movement.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Q1 2026 earnings release and conference call scheduled.
4/30/2026, 12:00:00 AM
Merck and Co Inc (MRK) · Earnings Release
Q1 2026 earnings release and conference call for 2026-04-30, estimated to have a low impact of ~1-2% based on historical trends, scheduled.
4/30/2026, 12:00:00 AM
Regeneron Pharmaceuticals Inc (REGN) · Earnings Release
Regeneron is scheduled to report its first quarter 2026 financial and operating results on 2026-04-29. Importance is Medium as earnings typically drive significant price movement, scheduled.
4/29/2026, 12:00:00 AM